Example: Heart Attack

Clinical Trials on Limited Systemic Sclerosis

Total 9 results

NCT01881529

Completed

A Non-Interventional Pilot Study Assessing Whether Lysyl Oxidase-like 2 (LOXL2) is Present in Subjects With Scleroderma

Conditions: Limited Scleroderma; Diffuse Scleroderma
NCT01072669

Completed

Efficacy of Ambrisentan in Limited Scleroderma Patients in Improving Blood Flow to Hands or Feet

Conditions: Ischemia
NCT02531009

Withdrawn

Systemic Sclerosis Clinical and Biomarker Study

Conditions: Healthy; Systemic Sclerosis
NCT01347008

Completed

Effect of Sildenafil on the Microcirculatory Blood Flow and Endothelial Progenitor Cells in Systemic Sclerosis

Conditions: Scleroderma, Systemic; Scleroderma, Diffuse; Scleroderma, Limited; Raynaud Phenomenon
NCT00812188

Completed

Treatment Study Comparing Medium or High Dose Uva-1 Treatment 3x/Week Versus Fluocinonide 0.05% Cream in the Treatment of Morphea.

Conditions: Symmetric Limited Morphea
NCT02298777

Recruiting

Metabolomic Analysis of Systemic Sclerosis

Conditions: Scleroderma (Limited and Diffuse); Undifferentiated Connective Tissue Disease; Raynaud Disease; Vascular Disease; Healthy Control Subjects
NCT02682511

Recruiting

Oral Ifetroban to Treat Diffuse Cutaneous Systemic Sclerosis (SSc) or SSc-associated Pulmonary Arterial Hypertension

Conditions: Scleroderma, Diffuse; Scleroderma, Systemic; Scleroderma, Limited; Sclerosis, Progressive Systemic; Skin Diseases; Connective Tissue Diseases; Pathologic Processes; Autoimmune Diseases
NCT00740285

Completed

Effectiveness and Safety of Lidocaine for Scleroderma

Conditions: Scleroderma
NCT00775463

Completed

Digital Ischemic Lesions in Scleroderma Treated With Oral Treprostinil Diethanolamine

Conditions: Systemic Sclerosis; Scleroderma